A Class of Reversible Primitive Recursive Functions

AbstractReversible computing is bi-deterministic which means that its execution is both forward and backward deterministic, i.e. next/previous computational step is uniquely determined. Various approaches exist to catch its extensional or intensional aspects and properties. We present a class RPRF of reversible functions which holds at bay intensional aspects and emphasizes the extensional side of the reversible computation by following the style of Dedekind-Robinson Primitive Recursive Functions. The class RPRF is closed by inversion, can only express bijections on integers — not only natural numbers —, and it is expressive enough to simulate Primitive Recursive Functions, of course, in an effective way

Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive disease, hardly curable with standard chemo-immunotherapy. Current approaches have greatly improved patients' outcomes, nevertheless the disease is still characterized by high relapse rates. Before approval by EMA, Italian patients with relapsed/refractory MCL were granted ibrutinib early access through a Named Patient Program (NPP). An observational, retrospective, multicenter study was conducted. Seventyseven heavily pretreated patients were enrolled. At the end of therapy there were 14 complete responses and 14 partial responses, leading to an overall response rate of 36.4%. At 40 months overall survival was 37.8% and progression free survival was 30%; disease free survival was 78.6% at 4 years: 11/14 patients are in continuous complete response with a median of 36 months of follow up. Hematological toxicities were manageable, and main extra-hematological toxicities were diarrhea (9.4%) and lung infections (9.0%). Overall, 4 (5.2%) atrial fibrillations and 3 (3.9%) hemorrhagic syndromes occurred. In conclusions, thrombocytopenia, diarrhea and lung infections are the relevant adverse events to be clinically focused on; regarding effectiveness, ibrutinib is confirmed to be a valid option for refractory/relapsed MCL also in a clinical setting mimicking the real world